Navigation Links
Win a $10,000 Education Fund for Your Miracle Child
Date:3/1/2010

PARSIPPANY, N.J., March 1 /PRNewswire/ -- If you are a parent who has conceived using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future.  Two other education fund prizes will also be awarded.  To be eligible, all you need to do is write a brief essay.  The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are coping with infertility and how you would describe your success using BRAVELLE® (urofollitropin for injection, purified) and/or MENOPUR® (menotropins for injection, USP) as part of your treatment plan.  

Ferring's My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE®  and/or MENOPUR®.  The contest celebrates the miracle of birth for parents who have faced infertility, and carries on Ferring's tradition of supporting patients by offering education funds for the winners' children.  

Ferring is also awarding a $7,500 education fund to the runner-up and $5,000 to an honorable mention winner.  Since announcing the first contest in 2004, Ferring has awarded $128,000 in education funds.

Essays should not exceed 2,000 words.  They must be written in English, include the entrant's name, address, phone number and age, as well as the child(ren)'s name(s) and age(s), and be submitted with a contest application and labeled digital photo.  Entries must be postmarked by December 31, 2010.  Winners will be announced in January 2011.

For more details and a contest application, visit www.ferringfertility.com or www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

MENOPUR® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program. BRAVELLE® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE® and MENOPUR®. BRAVELLE® and MENOPUR® are potent substances capable of causing mild to severe adverse reactions, including OHSS (overall incidence of 6.0% for BRAVELLE® and 3.8% for MENOPUR®), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE® and MENOPUR® are contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to respectively, urofollitropins, purified, and menotropins or MENOPUR®.

BRAVELLE® is contraindicated for the presence of any cause of infertility other than anovulation. MENOPUR® is contraindicated for sex hormone dependent tumors of the reproductive tract and accessory organs. BRAVELLE® and MENOPUR® are contraindicated in women who are pregnant. BRAVELLE® may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE® and menotropins when administered during pregnancy.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company.  Ferring Pharmaceuticals offers a line of products in the U.S. market.  They include: BRAVELLE®, MENOPUR® and REPRONEX® (menotropins for injection, USP), Novarel® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility.  For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

Please visit www.ferringfertility.com  for Full Prescribing Information for MENOPUR® and BRAVELLE®.

SOURCE Ferring Pharmaceuticals Inc.

Back to top

RELATED LINKS
http://www.ferringusa.com

'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sonic Innovations, Inc. Donates $10,000 to Feeding America
2. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
3. Lillys Online, Interactive Health Education Program Receives Two Web Awards
4. Spotsylvania Regional Medical Center Partners with TeleHealth Services for Integrated Patient Education
5. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
6. AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell
7. Hypoglycemia Education - A Vital Weapon in the Battle to Conquer Diabetes
8. Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care
9. Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation
10. Educational Video Series Released for American Diabetes Month
11. Family Medicine Education Consortium, Inc. Endorses PatientCarenet.Org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)... TORONTO , May 12, 2017  The China and ... low-pressure washing technology that consumes less water, energy and detergent, and ... their first product LaughingU, a shoebox-sized washing machine that washes and ... ... First Product, LaughingU, is compact, and does not require an external ...
(Date:5/10/2017)... WASHINGTON , May 10, 2017  The ... doctors or employees of sleep therapy clinics to ... a sleep therapy clinic is involved in a ... as interested in hearing from an employee of ... involved in a kickback scheme to provide medical practice ...
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
Breaking Medicine Technology:
(Date:5/22/2017)... , ... May 22, 2017 , ... ... of a larger group investing in InsightRX, an early stage company in San ... biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted as the ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... ABC Financial Services and financial systems. , Dozens of clubs using ABC ... are electronically processed through GetLinked into their club’s accounting system , The latest ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... brought together a cross-disciplinary group of scholars, policymakers, and activists wanting to address ... and Equity is the third book from a recent series of from ...
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... Following the ... New York became the first state to require that hospitals follow a protocol to ... in the medical community as to whether such steps would have saved Rory or ...
(Date:5/19/2017)... ... May 19, 2017 , ... A leader ... of Charlotte recently began recruitment efforts for the inaugural cohort of its ... skills, knowledge and expertise to approach and address the unique nuances healthcare organizations ...
Breaking Medicine News(10 mins):